Legend Biotech (LEGN) Cash from Financing Activities (2019 - 2025)
Legend Biotech (LEGN) posted Cash from Financing Activities of -$600000.0 for Q4 2025, down 189.55% on a QoQ basis from $670000.0 in Q3 2025, and down 100.0% year-over-year from -$inf billion in Q4 2024.
Legend Biotech (LEGN) has 7 years of Cash from Financing Activities data on file, last reported at -$600000.0 in Q4 2025.
- In Q4 2025, Cash from Financing Activities fell 100.0% year-over-year to -$600000.0; the TTM figure through Dec 2025 stood at -$253000.0 (down 104.41% YoY), while the FY2025 annual figure was -$300000.0, down 105.26% from the prior year.
- Cash from Financing Activities fell to -$600000.0 in Q4 2025, from $670000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $790.0 million in Q2 2023 and bottomed at -$990000.0 in Q2 2025.
- A 5-year average of $90.1 million and a median of $878000.0 in 2023 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 78200.1% in 2023, down 1876.0% in 2023.
- Year by year, Cash from Financing Activities stood at $323.6 million in 2021, then plunged by 100.24% to -$783000.0 in 2022, then soared by 218.14% to $925000.0 in 2023, then tumbled by 132.43% to -$300000.0 in 2024, then plunged by 100.0% to -$600000.0 in 2025.
- The last three Cash from Financing Activities figures came in at -$600000.0 (Q4 2025), $670000.0 (Q3 2025), and -$990000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 238.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -600,000.00 |
| Dec 31, 2025 | -600,000.00 |
| Sep 30, 2025 | 670,000.00 |
| Sep 30, 2025 | 670,000.00 |
| Jun 30, 2025 | -990,000.00 |
| Jun 30, 2025 | -990,000.00 |
| Mar 31, 2025 | 667,000.00 |
| Mar 31, 2025 | 667,000.00 |
| Dec 31, 2024 | -300,000.00 |
| Dec 31, 2024 | -300,000.00 |
| Sep 30, 2024 | 4.25 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Jun 30, 2024 | 955,000.00 |
| Jun 30, 2024 | 955,000.00 |
| Mar 31, 2024 | 831,000.00 |
| Mar 31, 2024 | 831,000.00 |
| Dec 31, 2023 | 925,000.00 |
| Dec 31, 2023 | 925,000.00 |
| Sep 30, 2023 | 961,000.00 |
| Sep 30, 2023 | 961,000.00 |
| Jun 30, 2023 | 790.05 Mn |
| Jun 30, 2023 | 790.05 Mn |
| Mar 31, 2023 | -444,000.00 |
| Mar 31, 2023 | -444,000.00 |
| Dec 31, 2022 | -783,000.00 |
| Dec 31, 2022 | -783,000.00 |
| Sep 30, 2022 | 377.73 Mn |
| Sep 30, 2022 | 377.73 Mn |
| Jun 30, 2022 | 1.01 Mn |
| Jun 30, 2022 | 1.01 Mn |
| Mar 31, 2022 | 25,000.00 |
| Mar 31, 2022 | 25,000.00 |
| Dec 31, 2021 | 323.56 Mn |
| Dec 31, 2021 | 323.56 Mn |
| Sep 30, 2021 | 1.14 Mn |
| Sep 30, 2021 | 1.14 Mn |
| Jun 30, 2021 | 301.75 Mn |
| Jun 30, 2021 | 301.75 Mn |
| Mar 31, 2021 | 207,000.00 |
| Mar 31, 2021 | 207,000.00 |
| Dec 31, 2020 | 661,000.00 |
| Dec 31, 2020 | 661,000.00 |
| Sep 30, 2020 | 9.66 Mn |
| Sep 30, 2020 | 9.66 Mn |
| Jun 30, 2020 | 459.80 Mn |
| Jun 30, 2020 | 459.80 Mn |
| Mar 31, 2020 | 148.76 Mn |
| Mar 31, 2020 | 148.76 Mn |
| Dec 31, 2019 | -6.68 Mn |
| Dec 31, 2019 | -6.68 Mn |
| Sep 30, 2019 | -154,000.00 |
| Sep 30, 2019 | -154,000.00 |
| Jun 30, 2019 | -7.18 Mn |
| Jun 30, 2019 | -7.18 Mn |